7707 Gateway Boulevard
United States - Map
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The companys HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has completed a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis. Its HuCNS-SC is also in Phase I/II clinical trials for the treatment of thoracic spinal cord injury; Phase II clinical trials for the treatment of cervical spinal cord injury; and Phase I/II clinical trials for dry age-related macular degeneration. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.
|Dr. Ian John Massey D.Phil,
Chief Exec. Officer, Pres and Director
|Mr. Gregory T. Schiffman MBA, CPA,
Chief Financial Officer and Exec. VP of Fin.
|Mr. Kenneth B. Stratton J.D., Esq.,
Gen. Counsel and Sec.
|Mr. Martin M. McGlynn ,
|Dr. Ann Tsukamoto Ph.D.,
Exec. VP of Scientific & Strategic Alliances
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|